Reports Q4 revenue $1.847M vs $1.82M last year. "We accomplished two of our key 2022 goals with the fourth quarter launches of Quell Fibromyalgia and DPNCheck 2.0," said Shai N. Gozani, M.D., Ph.D., Chief Executive Officer of NeuroMetrix. "These products address important unmet clinical medical needs. Our focus will now shift to successful commercialization of both products, which we believe will drive the Company’s long-term growth. At the same time, we will continue to invest in further technology advances consistent with our position as a leading innovator in the neurology and chronic pain sector."
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NURO:
- NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
- NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
- NeuroMetrix announces launch of DPNCheck 2.0
- NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
